These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 36775218)
21. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study. Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525 [TBL] [Abstract][Full Text] [Related]
22. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789 [TBL] [Abstract][Full Text] [Related]
23. Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review. Fu Y; Zhu W; Zhou Y; Chen H; Yan L; He W Am J Cardiovasc Drugs; 2020 Apr; 20(2):139-147. PubMed ID: 31485852 [TBL] [Abstract][Full Text] [Related]
24. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081 [TBL] [Abstract][Full Text] [Related]
25. Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation. Black-Maier E; Piccini JP; Granger CB J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2968-2976. PubMed ID: 31520437 [TBL] [Abstract][Full Text] [Related]
26. Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: A propensity-score matched study. Korsholm K; Valentin JB; Damgaard D; Diener HC; Camm AJ; Landmesser U; Hildick-Smith D; Johnsen SP; Nielsen-Kudsk JE Int J Cardiol; 2022 Sep; 363():56-63. PubMed ID: 35780932 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis. Bai Y; Guo SD; Deng H; Shantsila A; Fauchier L; Ma CS; Lip GYH Age Ageing; 2018 Jan; 47(1):9-17. PubMed ID: 28985259 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience. Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572 [TBL] [Abstract][Full Text] [Related]
29. Lower rate of major bleeding in very high risk patients undergoing left atrial appendage occlusion: A propensity score-matched comparison with direct oral anticoagulant. Magnocavallo M; Della Rocca DG; Vetta G; Mohanty S; Gianni C; Polselli M; Rossi P; Parlavecchio A; Fazia MV; Guarracini F; De Vuono F; Bisignani A; Pannone L; Raposeiras-Roubín S; Lochy S; Cauti FM; Burkhardt JD; Boveda S; Sarkozy A; Sorgente A; Bianchi S; Chierchia GB; de Asmundis C; Al-Ahmad A; Di Biase L; Horton RP; Natale A Heart Rhythm; 2024 Aug; 21(8):1267-1276. PubMed ID: 38246567 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289 [TBL] [Abstract][Full Text] [Related]
31. Left atrial appendage occlusion with the Amplatzer Cardiac Plug could improve survival and prevent thrombo-embolic and major bleeding events in atrial fibrillation patients with increased bleeding risk. Budts W; Laenens D; Van Calenbergh F; Vermeersch P; De Potter T; Aminian A; Benit E; Stammen F; Kefer J Acta Cardiol; 2016 Apr; 71(2):135-43. PubMed ID: 27090034 [TBL] [Abstract][Full Text] [Related]
32. Outcomes of cardiac surgery with left atrial appendage occlusion versus no Occlusion, direct oral Anticoagulants, and vitamin K Antagonists: A systematic review with Meta-analysis. Nso N; Nassar M; Zirkiyeva M; Lakhdar S; Shaukat T; Guzman L; Alshamam M; Foster A; Bhangal R; Badejoko S; Lyonga Ngonge A; Tabot-Tabot M; Mbome Y; Rizzo V; Munira MS; Thambidorai S Int J Cardiol Heart Vasc; 2022 Jun; 40():100998. PubMed ID: 35655531 [TBL] [Abstract][Full Text] [Related]
33. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis. Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404 [TBL] [Abstract][Full Text] [Related]
34. Comparing the Clinical Outcomes Observed with Rivaroxaban Versus Warfarin for the Management of Obese Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. Zhuo X; Wang J; Shao L Cardiovasc Drugs Ther; 2024 Feb; 38(1):79-89. PubMed ID: 35763193 [TBL] [Abstract][Full Text] [Related]
35. Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. Chan YH; Lee HF; Chao TF; Wu CT; Chang SH; Yeh YH; See LC; Kuo CT; Chu PH; Wang CL; Lip GYH Cardiovasc Drugs Ther; 2019 Dec; 33(6):701-710. PubMed ID: 31745687 [TBL] [Abstract][Full Text] [Related]
36. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis. Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Wang KL; Lopes RD; Patel MR; Büller HR; Tan DS; Chiang CE; Giugliano RP Eur Heart J; 2019 May; 40(19):1492-1500. PubMed ID: 30590440 [TBL] [Abstract][Full Text] [Related]
38. Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis. Kim IS; Kim HJ; Yu HT; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Pak HN J Cardiol; 2019 Jun; 73(6):515-521. PubMed ID: 30770140 [TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of short-term anticoagulant regimens after left atrial appendage occlusion: A systematic review and meta-analysis. Zhou Q; Liu X; Yang X; Huang XH; Wu YZ; Tao YY; Wei M Thromb Res; 2024 Jan; 233():88-98. PubMed ID: 38035647 [TBL] [Abstract][Full Text] [Related]
40. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Malik AH; Yandrapalli S; Aronow WS; Panza JA; Cooper HA Heart; 2019 Sep; 105(18):1432-1436. PubMed ID: 31203254 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]